CB03-154

DRUG3 trials

Sponsors

Shanghai Zhimeng Biopharma, Inc.

Conditions

Focal EpilepsyHealthy Volunteers

Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants

Shanghai Zhimeng Biopharma, Inc.Healthy Volunteers

Start: 2022-05-02End: 2023-03-02Target: 70Updated: 2022-08-16

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia

CompletedNCT05502549

Shanghai Zhimeng Biopharma, Inc.Healthy Volunteers

Start: 2022-11-29End: 2023-12-15Updated: 2024-02-01

Phase 2

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

RecruitingNCT07238868

Shanghai Zhimeng Biopharma, Inc.Focal Epilepsy

Start: 2025-08-14End: 2029-06-30Target: 144Updated: 2025-11-20